Detalhe da pesquisa
1.
Absorption, distribution, metabolism, and excretion of mTOR kinase inhibitor CC-223 in rats, dogs, and humans.
Xenobiotica
; 49(1): 43-53, 2019 Jan.
Artigo
Inglês
| MEDLINE | ID: mdl-29206565
2.
Assessment of drug-drug interaction potential and PBPK modeling of CC-223, a potent inhibitor of the mammalian target of rapamycin kinase.
Xenobiotica
; 49(1): 54-70, 2019 Jan.
Artigo
Inglês
| MEDLINE | ID: mdl-29297772
3.
Safety, Pharmacokinetics, and Antifibrotic Activity of CC-90001 (BMS-986360), a c-Jun N-Terminal Kinase Inhibitor, in Pulmonary Fibrosis.
Clin Pharmacol Drug Dev
; 12(8): 779-789, 2023 Aug.
Artigo
Inglês
| MEDLINE | ID: mdl-37378860
4.
Pharmacokinetics and tolerability of apremilast in healthy Korean adult men.
Clin Transl Sci
; 14(4): 1505-1511, 2021 07.
Artigo
Inglês
| MEDLINE | ID: mdl-33932093
5.
Impact of Renal Impairment on the Pharmacokinetics of Apremilast and Metabolite M12.
Clin Pharmacol Drug Dev
; 5(6): 469-479, 2016 Nov.
Artigo
Inglês
| MEDLINE | ID: mdl-27870479